The Gynecologic Oncology Program at the Susan F. Smith Center for Women’s Cancers at Dana-Farber is a leader in research and care for patients with gynecologic cancer, including ovarian cancer, endometrial/uterine cancer, cervical cancer, vulvar cancer, and vaginal cancers, as well as gestational trophoblastic disease. We offer a seamless blend of medical, surgical, radiation, and pathology expertise and develop personalized approaches based on each patient’s specific type of cancer, whether it is early-stage or advanced. Our physicians focus exclusively on the diagnosis and treatment of gynecologic cancers. As one of the world's leading centers for cancer treatment and research, we're able to offer diagnostic tests and therapies based on the most up-to-date scientific findings, including the latest clinical trials.
Featured Items |view more
News
Innovative Endometrial Cancer Research Offers Fresh Promise for Patients
For the past decade, new cases of endometrial (uterine) cancer have been on the rise in the United States. The past few years, however, have brought a more promising rise: A new generation of drugs and drug combinations that are improving ...
News
Early Action, Better Outcomes: Transforming Cancer Prevention
For more than 100 years, health advocates have spread the message that, with cancer, patience is not a virtue.
News
CAR memory-like NK cells targeting the membrane proximal domain of mesothelin demonstrate promising activity in ovarian cancer
News
Finding New Vulnerabilities in Uterine and Ovarian Cancers
Just like humans, cells get stressed, too — especially cancer cells. For decades, Dana-Farber researchers have been characterizing a complex molecular condition in cancer cells known as DNA replication stress.
News
Physician-scientists at Dana-Farber Cancer Institute have received a five-year, $15 million Program Project Grant from the National Cancer Institute (NCI) for research in endometrial cancer, which arises in the inner lining of the uterus ...
News
Antibody-Drug Conjugates: A Cancer Therapy Revolution
Dana-Farber researchers explore how a novel therapy may benefit patients
